Brief: 4DMT Presents Positive Interim Data From Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial In Patients With Wet AMD At ARVO 2023

4D Molecular Therapeutics

27/04/2023 12:30

April 27 (Reuters) - 4D Molecular Therapeutics Inc
 FDMT.O :
    * 4DMT PRESENTS POSITIVE INTERIM DATA FROM INTRAVITREAL
4D-150
PHASE 1/2 PRISM CLINICAL TRIAL IN PATIENTS WITH WET AMD AT ARVO
2023
    * 4D MOLECULAR THERAPEUTICS INC - INTRAVITREAL 4D-150 WAS
WELL-TOLERATED WITH NO INFLAMMATION IN 14 OF 15 PATIENTS
    * 4D MOLECULAR THERAPEUTICS INC -  NO DOSE-LIMITING
TOXICITIES,
TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED ACROSS ALL
THREE DOSE COHORTS

Source text for Eikon:  ID:nGNX3n1Dd4 
Further company coverage:  FDMT.O 

 ((Reuters.Briefs@thomsonreuters.com;))